Evidence map›Paper›PMID 39508500›Full record

SynthesisActa dermato-venereologica2024

A Systematic Review of 207 Studies Describing Validation Aspects of the Dermatology Life Quality Index.

Jui Vyas, Jeffrey R Johns, Faraz M Ali, John R Ingram, Sam Salek, Andrew Y Finlay

Registry-linked trialAbstract readSystematic Review
In one paragraph

Synthesis in Acta dermato-venereologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06980961 (Short-pulse and Ultra-Short Pulse ND), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06980961 narecruitingnot on this mapstarted 2025, after this paper: background citation

Short-pulse and Ultra-Short Pulse ND: YAG 1064 Lasers for Stasis Dermatitis Secondary to Chronic Venous Hypertension Treatment: the SUPERSTAR Trial

TypeinterventionalSponsorScience Valley Research InstituteRan2025 to 2026Enrolled20ConditionsStasis DermatitisArmsshort-pulse ND: YAG 1064 laser, ultra-short-pulse ND: YAG 1064 laser, cold cream
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jui VyasCentre for Medical Education, School of Medicine, Cardiff University, Cardiff, UK. vyasjj@cardiff.ac.uk.ORCID 0000-0003-2839-2651
Jeffrey R JohnsDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Faraz M AliDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0002-4184-2023
John R IngramDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0002-5257-1142
Sam SalekSchool of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.ORCID 0000-0002-4612-5699
Andrew Y FinlayDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0003-2143-1646

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study systematically analysed peer-reviewed publications describing validation aspects of the Dermatology Life Quality Index (DLQI) and used Naicker's Critically Appraising for Antiracism Tool to assess risk of racial bias. Seven online databases were searched from 1994 until 2022 for articles containing DLQI validation data. Methodology followed PRISMA guidelines, the protocol was registered in PROSPERO, and articles reviewed independently by two assessors. Of 1,717 screened publications, 207 articles including 58,828 patients from >  49 different countries and 41 diseases met the inclusion criteria. The DLQI demonstrated strong test-retest reliability; 43 studies confirmed good internal consistency. Twelve studies were performed using anchors to assess change responsiveness with effect sizes from small to large, giving confidence that the DLQI responds appropriately to change. Forty-two studies tested known-groups validity, providing confidence in construct and use of the DLQI over many parameters, including disease severity, anxiety, depression, stigma, scarring, well-being, sexual function, disease location and duration. DLQI correlation was demonstrated with 119 Patient Reported Outcomes/Quality of Life measures in 207 studies. Only 15% of studies explicitly recruited minority ethnic participants; 3.9% stratified results by race/ethnicity. This review summarizes knowledge concerning DLQI validation, confirms many strengths of the DLQI and identifies areas for further validation.

Indexed as

DermatologyQuality of LifeSkin DiseasesHumansPatient Reported Outcome MeasuresPredictive Value of TestsRacismReproducibility of ResultsSurveys and Questionnaires

Identifiers

PMID39508500
PMCPMC11559262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.